GSK Secures FDA Nod for First Oral Carbapenem Antibiotic Utebzi
Event summary
- GSK's Utebzi (tebipenem pivoxil) approved by the FDA for treating complicated urinary tract infections (cUTIs) in adults.
- First and only oral carbapenem antibiotic, offering an alternative to intravenous treatments.
- Approval based on positive Phase III PIVOT-PO trial results, showing non-inferiority to IV imipenem-cilastatin.
- Utebzi expected to be available to US patients by the end of 2026.
- GSK licensed the drug from Spero Therapeutics under an exclusive global agreement.
The big picture
The approval of Utebzi addresses a critical gap in treating cUTIs, particularly those caused by multidrug-resistant pathogens. With over 3 million cases annually in the US and significant healthcare costs, this innovation could reduce hospital resource use and improve patient outcomes. GSK's strategic move strengthens its position in the anti-infectives market, aligning with broader industry efforts to combat antibiotic resistance.
What we're watching
- Market Adoption
- The pace at which Utebzi gains market share against existing IV treatments for cUTIs.
- Revenue Impact
- Whether GSK can leverage this approval to drive significant revenue growth in its anti-infectives portfolio.
- Competitive Response
- How competitors in the antibiotic space react to the introduction of the first oral carbapenem.
Related topics